SEALSQ Increased Its Quantum Investment Fund to Over $35 Million and Provides Update on Strategic Quantum Technology Convergence July 7, 2025
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3 July 7, 2025